Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial Meeting Abstract
| Authors: | Fradet, Y.; Bellmunt, J.; De Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Necchi, A.; Gerritsen, W. R.; Gurney, H.; Quinn, D. I.; Culine, S.; Sternberg, C. N.; Nam, K.; Frenkl, T. L.; Perini, R. F.; Bajorin, D. F. |
| Abstract Title: | Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 246s |
| Language: | English |
| ACCESSION: | WOS:000442916002048 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4521 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4521 -- Source: Wos |
